What changed from existing technology?
This study looked at how TP53 gene changes affect the survival of patients with a type of blood cancer called acute myeloid leukaemia after they receive a bone marrow transplant.
This study is the first to specifically analyze the outcomes of TP53-mutated AML patients after allogeneic hematopoietic cell transplantation, highlighting the significant impact of TP53 mutations on survival and relapse rates.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
gle-centre analysis of 61 consecutive TP53-altered AML patients undergoing first allogeneic haematopoietic cell transplantation (allo-HCT) at the Medical Cent
Abstract ↗outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation. TP53 mutations define a clinically distinct subset of acute mye
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The findings suggest that TP53 mutation status could be used to identify AML patients at higher risk of poor outcomes after allogeneic hematopoietic cell transplantation, potentially guiding treatment decisions.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.